Argumentacion para el tratamiento psicofarmacologico y biologico del trastorno obsesivo-compulsivo resistente y refractario. Articulo de revision
Autor: Dra. Teraiza E. Mesa Rodríguez | Publicado:  31/01/2012 | Articulos , Psiquiatria , Psicologia | |
Tratamiento psicofarmacologico y biologico trastorno obsesivo-compulsivo resistente refractario .6

124. W.K., Rudorfer, V. (Ed.) et-al., Obsessive-compulsive disorder: Contemporary issues in treatment. Personality and clinical psychology series (pp. 277-302). Mahwah, NJ, US: Lawrence Erlbaum Associates, Inc., Publishers.
125. Keuneman JR, Pokos V, Weerasundera R. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 2005;39(5):336-43.
126. Denys D, Zohar J, Westenberg H. The Role of dopamine in obsessive-compulsive disosrder: preclinical and clinical evidence. J Clin Psychiatry 2004;65(suppl.14):11-17.
127. Li X, May RS, Tolbert LC. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66(6):736-43.
128. van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van Den Brink W, Linszen D: Obsessive compulsive symptoms in a randomized double blind study with olanzapine or risperidone in young patients with recent onset schizophrenia or related disorders. Schizophr Res 2006; 81(suppl): 99-100.
129. Linszen D: Obsessive compulsive symptoms in a randomized double blind study with olanzapine or risperidone in young patients with recent onset schizophrenia or related disorders. Schizophr Res 2006; 81(suppl): 99-100.
130. Ertugrul A, Yagcioglu AEA, Eni N, Yazici KM: Obsessive-compulsive symptoms in clozapine-treated schizophrenia patients. Psychiatry Clin Neurosci 2005; 59: 219-222.
131. Ongur D, Goff DC: Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 2005; 75: 349-362.
132. Warneke L: A possible new treatment approach to obsessive-compulsive disorder. Can J Psychiatry 1997; 42: 667-668
133. Li X, May RS, Tolbert LC, et al. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005; 66: 736-743.
134. Yaryura – Tobías J. A., Neziroglu F. A. Obsessive compulsive disorders: pathogenesis, diagnosis and treatment. New York, USA. Marcel Dekker; 1983
135. Yaryura – Tobías J. A., Neziroglu F. A. Trastornos Obsesivo – Compulsivos. Harcourt Brace de España S.A.; 1997
136. Yaryura -Tobías J. A., Neziroglu F. A, Pérez Rivera R, Borda T. “Tratamiento del Trastorno Obsesivo-Compulsivo”. Revista de Psiquiatría del Uruguay 66; 1, 2002; 47-55
137. Yaryura Tobías JA, Neziroglu F, Pérez Rivera RL. “Teoría unificada del trastorno obsesivo-compulsivo”. Acta Psiquiát Psicol Am Lat 45, (4), 1999, 339-347.
138. Yaryura Tobías JA, Neziroglu F. “Teorema del trastorno obsesivo-compulsivo”. Salud Mental 24, (2), 2001, 11-16.
139. Yaryura-Tobias, J.A., & Neziroglu, F.A.. Obsessive-compulsive disorder spectrum. Washington, DC: American Psychiatric Press 1997; 33-65
140. F Arias Horcajadas La risperidona seria efectiva para el tratamiento del trastorno obsesivo compulsivo resistente al tratamiento siic salud 16 de Noviembre, 2006.
141. Hood, S., Alderton, D. y Castle, D. (2001). Obsessive-compulsive disorder: Treatment and treatment resistance. Australasian Psychiatry, 9(2), 118- 127
142. W.K., Rudorfer, V. (Ed.) et-al., Obsessive-compulsive disorder: Contemporary
issues in treatment. Personality and clinical psychology series (pp. 277-302). Mahwah, NJ, US: Lawrence Erlbaum Associates, Inc., Publishers.
143. Shetti CN, Reddy YC, Kandavel T, et al. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 2005; 66: 1517-1523.
144. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitivebehavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial. J Clin Psychiatry 1999; 60: 584-590.
145. Simpson HB, Huppert JD, Petkova E, et al. Response versus remission in obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 269-276.
146. Toro-Martínez E. Manejo farmacológico del trastorno obsesivo compulsivo resistente al tratamiento. Vertex, Rev Arg Psiquiat 2005; 16 (64): 442-445.
147. Math SB, Janardhan Reddy. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int J Clin Practice 2007; 61: 1188-1197.
148. McDougle CJ, Epperson CN, Pelton Gh, et al. A doubleblind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794-801.
149. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302-308.
150. Maina G, Albert U, Ziero S, et al. Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?. Int Clin Psychopharmacol 2003; 18: 23-28.
151. Math SB, Janardhan Reddy. Issues in the pharmacological treatment of obsessive-compulsive disorder. Int J Clin Practice 2007; 61: 1188-1197.
152. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1812-1814.
153. Wikinski S. Tratamiento farmacológico de los trastornos de ansiedad. En: Wikinski S, Jufe G. El tratamiento farmacológico en Psiquiatría. Editorial Panamericana, Buenos Aires, 2004.
154. Ertugrul A, Yagcioglu AEA, Eni N, Yazici KM: Obsessive-compulsive symptoms in clozapine-treated schizophrenia patients. Psychiatry Clin Neurosci 2005; 59: 219-222.
155. Maina G, Albert U, Ziero S, Bogetto F. “Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?”. Int Clin Psychopharmacol 2003; 18:23–28.
156. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. “Lack of efficacyof clozapine monotherapy in refractory obsessivecompulsive disorder”. Am J Psychiatry 1995; 152:1812–1814.
157 Stamouli S, Lykouras L: Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006; 26: 396-400.
158. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Arlington, VA: American Psychiatric Association, 2007
159. Cia AH, Pérez Rivera R, Flichman A. “Farmacoterapia”. Cia AH. El Trastorno Obsesivo-Compulsivo y su Espectro. Bs As, Polemos 2007; 135-166.
160. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. “The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients”. J Clin Psychiatry 2005; 66:49–51.
161. Crane DL. “Ziprasidone as an augmenting agent in the treatment of anxiety-spectrum disorders”. CNS Spectr 2005; 10:176–179.
162. Denys D, Zohar J, Westenberg HG. ”The role of dopamine in obsessive- compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry, 65 Suppl 14, 2004; 11-7
163. Friedman SAballah TA, Mohamed O, et al. “Aripiprazole augmentation of clomipramine refractory obsessive-compulsive disorder”. J Clin Psychiatry 68, 6, june 2007
164. Goodman WK, McDougle CJ, Price LH, et al. “Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 51, 1990; 36-43
165. Hollander E, Baldini RN, Sood E, Pallanti S. “Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study”. Int J Neuropsychopharmacol 2003; 6:397–401.
166. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. “Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study”. J Clin Psychiatry 2005; 66:736–743.
167. Maina G, Albert U, Ziero S, Bogetto F. “Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?”. Int Clin Psychopharmacol 2003; 18:23–28.
168. McDougle CJ, Wayne KG, et al. ”Dopamine Antagonists in Tic-Related and Psychotic Spectrum Obsessive Compulsive Disorder”. J Clin Psychiatry 55, (3), 1994, 24-31
169. Pérez Rivera R, . “El Espectro Obsesivo-Compulsivo”. Cia AH. El Trastorno Obsesivo-Compulsivo y su Espectro. Bs As, Polemos 2007; 223-238
170. Skapinakis P, Papatheodorou T, Mavreas V. “Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trials”. European Neuropsychopharmacology 17, 2007; 79-93
171. Wikinski S. Tratamiento farmacológico de los trastornos de ansiedad. En: Wikinski S, Jufe G. El tratamiento farmacológico en Psiquiatría. Editorial Panamericana, Buenos Aires, 2004.
172. Li X, May RS, Tolbert LC. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66(6):736-43.
173. Misri S, Milis L. Obsessive-compulsive disorder in the postpartum open-label trial of quetiapine augmentation. J Clin Psychopharmacol 2004;24(6):624-7.
174. Denys D, de Geus F, van Megen H. A double-blind, randomized, placebo-control trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65(8):1040-1048.
175. Skapinakis P, Papatheodorou T, Mavreas V. “Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: A meta-analysis of the randomized controlled trials”. European Neuropsychopharmacology 17, 2007; 79-93
176. Yaryura – Tobías J. A., Neziroglu F. A. Obsessive compulsive disorders: Pathogenesis, diagnosis and treatment. New York, USA. Marcel Dekker; 1983
177. Yaryura – Tobías J. A., Neziroglu F. A. Trastornos Obsesivo – Compulsivos. Harcourt Brace de España S.A.; 1997
178. Yaryura -Tobías J. A., Neziroglu F. A, Pérez Rivera R, Borda T. “Tratamiento del Trastorno Obsesivo-Compulsivo”. Revista de Psiquiatría del Uruguay 66; 1, 2002; 47-55
179. Yaryura Tobías JA, Neziroglu F, Pérez Rivera RL. “Teoría unificada del trastorno obsesivo-compulsivo”. Acta Psiquiát Psicol Am Lat 45, (4), 1999, 339-347.
180. Yaryura Tobías JA, Neziroglu F. “Teorema del trastorno obsesivo-compulsivo”. Salud Mental 24, (2), 2001, 11-16.
181. Yaryura-Tobias, J.A., & Neziroglu, F.A.. Obsessive-compulsive disorder spectrum. Washington, DC: American Psychiatric Press 1997; 33-65
182. Hollander E, Baldini RN, Sood E, Pallanti S. “Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study”. Int J Neuropsychopharmacol 2003; 6:397–401.
183. Insel TR, Akiskal HS. Obsessive-compulsive disorder with psychotic features: a phenomenologic analysis”. Am J Psychiatry 143, 1986, 1527-1533.
184. Jenike MA, Baer l, et al.”Concomitant obsessive-compulsive disorder and schizotypal personality disorder. Am J Psychiatry 143, 1986, 530-532.
185. Jenike M. “An update on obsessive-compulsive disorder”. Bulletin of the Menninger Clinic. 65, 2001; 4-25
186. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. “Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study”. J Clin Psychiatry 2005; 66:736–743.
187. Liceaga R, Pérez Rivera R. “Epidemilogía del trastorno obsesivo compulsivo (TOC)”. Cia AH. El Trastorno Obsesivo-Compulsivo y su Espectro. Bs As, Polemos 2007; 51-66
188. Maina G, Albert U, Ziero S, Bogetto F. “Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?”. Int Clin Psychopharmacol 2003; 18:23–28.
189. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK. “A double-blind, placebocontrolled trial of olanzapine addition in fluoxetinerefractory obsessive-compulsive disorder”. Biol Psychiatry 2004; 55:553–555.
190. Yaryura-Tobias, J.A., & Neziroglu, F.A.. Obsessive-compulsive disorder spectrum. Washington, DC: American Psychiatric Press 1997; 33-65
191. Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M: Double-blind treatment with oral morphine in treatment-resistant obsessive- compulsive disorder. J Clin Psychiatry 2005; 66: 353-359.
192. Hollander E, Pallanti S. Current and experimental therapeutics of OCD. En Neuropsychopharmacology, The Fifth Generation of Progress. Davis KL, Charney D, Coyle JT, Nemeroff Ch editors. 5º ed. Lipincott Williams & Wilkins: Philadelphia;2002. p. 1647-64.
193. Pallanti S, Hollander E, Goodman WK. A Qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 2004;65(suppl 14):6-10.


Revista Electronica de PortalesMedicos.com
INICIO - NOVEDADES - ÚLTIMO NÚMERO - ESPECIALIDADES - INFORMACIÓN AUTORES
© PortalesMedicos, S.L.
PortadaAcerca deAviso LegalPolítica de PrivacidadCookiesPublicidadContactar